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Abstract: Gout is an inflammatory arthritis due to the joint deposition of monosodium urate (MSU)
crystals. Phagocytosis of MSU crystals by tissue macrophages results in the generation of reactive
oxygen species (ROS) and production of inflammatory cytokines and chemokines. Colchicine use in
gout is limited by severe toxicity. CD44 is a transmembrane glycoprotein that is highly expressed in
tissue macrophages and may be involved in gout pathogenesis. The P6 peptide is a 20-amino acid
residue peptide that binds to CD44. We hypothesized that the conjugation of colchicine to the P6 peptide
would reduce its off-target cytotoxicity while preserving its anti-inflammatory effect. A modified
version of P6 peptide and colchicine-P6 peptide conjugate were synthesized using Fmoc/tBu solid-phase
and solution-phase chemistry, respectively. A glutaryl amide was used as a linker. The P6 peptide was
evaluated for its binding to CD44, association, and internalization by macrophages. Cytotoxic effects of
P6 peptide, colchicine, and colchicine-P6 peptide on macrophages were compared and the inhibition of
ROS generation and interleukin-8 (IL-8) secretion in MSU-stimulated macrophages treated with P6
peptide, colchicine, or colchicine-P6 peptide was studied. We confirmed that the P6 peptide binds
to CD44 and its association and internalization by macrophages were CD44-dependent. Colchicine
(1, 10, and 25 µM) demonstrated a significant cytotoxic effect on macrophages while the P6 peptide and
colchicine-P6 peptide conjugate (1, 10 and 25 µM) did not alter the viability of the macrophages. The P6
peptide (10 and 25 µM) reduced ROS generation and IL-8 secretion mediated by a reduction in MSU
phagocytosis by macrophages. The colchicine-P6 peptide significantly reduced ROS generation and IL-8
secretion compared to the P6 peptide alone at 1 and 10 µM concentrations. Conjugation of colchicine to
the P6 peptide reduced the cytotoxic effect of colchicine while preserving its anti-inflammatory activity.
Keywords: CD44; colchicine; gout; hyaluronic acid; MSU; colchicine-peptide conjugate

1. Introduction
Gout is a prevalent inflammatory arthritis due to the precipitation of serum uric acid into crystallized
deposits of monosodium urate (MSU) crystals in and around the joint [1–3]. On a worldwide level,
it is estimated that between 1 and 3% of males and females, respectively, between the ages of 40 and
60 years old suffer from gout [4]. Gout flares are characterized by acute episodes of intense pain,
severe inflammation, and joint swelling, with the knee and metatarsophalangeal joints most frequently
affected [1,3]. Management of acute gout flares remains suboptimal, and hospitalizations due to poorly
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controlled flares have significantly increased over the past two decades [5–8]. Treatment modalities
of acute gout flares include the use of nonsteroidal anti-inflammatory drugs (NSAIDs), selective
cycloxygenase-2 (COX2) enzyme inhibitors, colchicine, and corticosteroids [9,10]. However, the use of
these agents is not without harm, given the comorbidities seen in older patients with gout [11–13].
The normal synovium contains two types of intimal cells: type A macrophages and type B
synovial fibroblasts [14]. During an acute episode of gouty arthritis, deposition of MSU crystals
in joints stimulates resident macrophages to produce the inflammatory cytokine interleukin-1 beta
(IL-1β) and inflammatory chemokines, interleukin-8 (IL-8), and monocyte chemoattractant protein-1
(MCP-1) [15,16]. The secretion of IL-8 results in the recruitment of inflammatory cells (e.g., neutrophils
and monocytes) to the affected joints [16–18]. This inflammatory cascade is mediated by phagocytosis
of MSU crystals by joint resident macrophages [19,20]. The mechanism of phagocytosis is not entirely
understood and the toll-like pattern recognition family of receptors (TLRs) may play a role in facilitating
crystal phagocytosis [21,22]. Subsequent to MSU crystal phagocytosis, reactive oxygen species (ROS)
are generated through the activation of NADPH oxidase and downstream activation of NLRP3
inflammasome and nuclear factor kappa-b (NF-κB), resulting in the expression and production of
IL-1β and IL-8 [23–25].
The cluster determinant-44 (CD44) receptor is a single pass transmembrane glycoprotein that
has various functions in cell division, migration, adhesion, and signaling [26]. CD44 expression level
in the synovium may be linked to the inflammatory status of the joint with increased expression of
certain isoforms over the course of experimental arthritis and in patients with advanced osteoarthritis
(OA) [27–29]. The CD44 receptor may also fulfill a phagocytic function in immune cells [30]. A number
of endogenous ligands to CD44 have been identified including high molecular weight hyaluronic
acid (HA) and the glycoprotein, proteoglycan-4 (PRG4), two major components of joint synovial fluid
(SF) [31]. Binding of HA and PRG4 to CD44 on the surface of macrophages was shown to result in
ligand internalization [32,33]. Furthermore, we have previously shown that recombinant human
PRG4 inhibits MSU phagocytosis by macrophages in a mechanism that may involve CD44 and/or TLR
receptor interactions [33]. The utility of CD44 as a targeting receptor on macrophages was also reported
by utilizing HA-coated nanoparticles to repolarize inflammatory macrophages to an anti-inflammatory
phenotype [34,35].
Colchicine is a natural alkaloid that is used in the management of acute gout flares as well as
prophylaxis against acute gout attacks within six months of initiating chronic urate-lowering therapy [36].
In addition to its use in gout, colchicine has also shown clinical efficacy in reducing pain and inflammation
in symptomatic OA, treatment of inflammation in crystal-induced chondrosis due to deposition of calcium
pyrophosphate crystals, and may also have a clinical benefit in lowering cardiovascular risk in patients
with coronary artery disease [36,37]. Due to its ability to interfere with microtubule assembly, colchicine
can control numerous cell functions, including cytokine and chemokine secretion and inflammatory cell
migration and proliferation [36]. This microtubule disrupting effect was also shown to block cancer cells
in the G2/M phase, thus its cytotoxic effect may prove useful for cancer treatment [38]. The therapeutic
effect of colchicine on macrophages in the context of MSU induced inflammation was shown to lie
upstream of microtubule disruption via inhibition of ROS generation [39]. Due to its off-target cytotoxicity,
oral colchicine use is limited by its gastrointestinal toxicity and drug–drug interactions, particularly
in patients with renal and hepatic impairments resulting in toxic outcomes (e.g., myopathy and liver
damage) [36,37]. In addition, fatalities have been reported due to both accidental and therapeutic
colchicine poisoning [40].
Localized drug delivery into the joint is one potential approach to enhance the joint residence time
of injected therapeutics and reduce systemic exposure of administered therapeutics. The joint half-life
estimates of small molecules and recombinant proteins following intra-articular administration is in the
order of hours due to rapid systemic clearance [41,42]. Encapsulation of small molecules and proteins
in microspheres offers the advantage of extending their joint residence time and reducing systemic
exposure [43,44]. Given the complexity of formulating microsphere delivery systems, peptide-drug
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conjugates (PDC) may offer an outstanding alternative approach to deliver small molecules selectively
to cells or specific targets, thereby enhancing their efficacy and reducing off-target interactions. PDCs
represent an important class of prodrugs that are formed through covalent binding of a specific
peptide sequence to a drug via a cleavable linker [45]. Given its importance in inflammatory joint
disease, CD44 receptor targeting may offer a unique opportunity to deliver intra-articular therapeutics
for the treatment of joint inflammatory diseases. The P6 peptide, FDAIAEIGNQLYLFKDGKYW,
is a novel CD44-binding peptide that was identified from studying the interaction of pro matrix
metalloproteinase-9 (pro-MMP-9) with CD44 as it relates to the proliferation of chronic lymphocytic
leukemia (CLL) cells [46]. The P6 peptide was shown to effectively prevent pro-MMP-9 CD44-dependent
binding to CLL cells [46].
The overall objective of this study was to evaluate the feasibility of conjugating the P6 peptide to
N-deacetylcolchicine via a hydrolyzable linker and study the efficacy and safety of the colchicine-P6
peptide conjugate in an in vitro model of MSU stimulated macrophages. We hypothesized that conjugation
of colchicine to the P6 peptide will modify colchicine’s intracellular distribution, thereby reducing its
cytotoxic effect while preserving its anti-inflammatory efficacy. We assessed the anti-inflammatory
efficacy using a combination of IL-8 secretion and ROS generation. We initially studied CD44 expression
in macrophages and characterized the role of CD44 in mediating MSU crystal uptake by macrophages.
We also evaluated the affinity of P6 binding toward the CD44 receptor using HA as a comparator.
We studied the association and internalization of fluorescently-labeled P6 peptide in human THP-1
macrophages. Subsequently, we studied the impact of P6 peptide, colchicine, and colchicine-P6 peptide
treatments on MSU phagocytosis by macrophages, macrophage cell viability, production of IL-8, and
ROS generation. Finally, we evaluated the stability of the P6 peptide in SF aspirates from donors with no
history of degenerative joint disease.
2. Results and Discussion
2.1. Synthesis of P6 Peptide
Modified P6 peptide H2 N-WYKGDKFLYLQNGIEAIADF-CO-NH2 in reverse order was assembled
on a Fmoc Rink amide resin using Fmoc solid-phase synthesis starting with Fmoc-L-phenylalanine
(Fmoc-Phe-OH). Fmoc deprotection was done by adding 20% piperidine in dimethylformamide (DMF)
(v/v). The modified version of the P6 peptide may not exhibit a similar behavior, even if all of the
amino acids and side chains in the sequence are the same. The subsequent Fmoc-protected amino
acids were coupled to the peptide template until the last amino acid Fmoc-Trp(Boc)-OH was coupled.
The final Fmoc deprotection was carried out to make a free N-terminal tryptophan residue for the
conjugation of colchicine, as shown in Scheme 1. After finishing the synthesis of the 20-amino acid
sequence of the P6 peptide, the linear peptide was confirmed by mass spectrometry analysis (Figure S1,
Supplementary Materials).
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Scheme 1 also depicts the chemical reaction between the P6 peptide-attached resin and 5(6)Scheme 1 also depicts the chemical reaction between the P6 peptide-attached resin and
carboxyfluorescein diisobutyrate. Protected P6 peptide-attached resin was used in the coupling with
5(6)-carboxyfluorescein diisobutyrate. Protected P6 peptide-attached resin was used in the coupling
5(6)-carboxyfluorescein diisobutyrate on a solid support in the presence of PyBOP, HOBt, and
with 5(6)-carboxyfluorescein diisobutyrate on a solid support in the presence of PyBOP, HOBt, and
DIPEA. After the purification of the crude peptide via reversed-phase HPLC and lyophilization, the
DIPEA. After the purification of the crude peptide via reversed-phase HPLC and lyophilization,
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2.5. Characterization of CD44 Receptor Expression on Macrophages, Regulation under Conditions of
2.5.
Characterization of CD44 Receptor Expression on Macrophages, Regulation under Conditions of
Inflammation and Role of CD44 in Modulating Monosodium Urate (MSU) Crystal Phagocytosis by
Inflammation and Role of CD44 in Modulating Monosodium Urate (MSU) Crystal Phagocytosis by
Macrophages
Macrophages
Human THP-1 macrophages express the CD44 receptor as shown by flow cytometry (Figure
Human THP-1 macrophages express the CD44 receptor as shown by flow cytometry (Figure 1A).
1A). CD44 surface expression increased when THP-1 macrophages were treated with IL-1β (10
CD44 surface expression increased when THP-1 macrophages were treated with IL-1β (10 ng/mL)
ng/mL) (p < 0.01) or soluble uric acid (UA; 10 mg/dL) (p < 0.001) compared to the untreated control
(p < 0.01) or soluble uric acid (UA; 10 mg/dL) (p < 0.001) compared to the untreated control macrophages
macrophages (Figures 1A,B). The magnitude of enhancement in the cell surface CD44 protein staining
(Figure
1A,B). The magnitude of enhancement in the cell surface CD44 protein staining subsequent to
subsequent to IL-1β was approximately two-fold compared to approximately 3-fold enhancement
IL-1β
was
two-fold
compared
to approximately
enhancement
with
UA treatment.
with UAapproximately
treatment. UA
treatment
increased
CD44 protein 3-fold
expression
by THP-1
macrophages
UA treatment increased CD44 protein expression by THP-1 macrophages compared to IL-1β treatment
(p < 0.01, Figure 1C). This is a significant finding as patients with chronic gout often have persistent
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hyperuricemia and detectable IL-1β levels in inflamed joints [47]. Given that the CD44 receptor
is upregulated under conditions of inflammation specific to gout, CD44 is plausibly an attractive
candidate for targeting intracellular therapeutics for intra-articular administration that would otherwise
be rapidly cleared from the joint [41]. We have further investigated the direct role that CD44 may play
in facilitating MSU crystal uptake by macrophages. Bone marrow-derived macrophages (BMDMs)
from CD44 wild-type animals (Cd44+/+ ) appeared to internalize MSU crystals to a greater extent
when compared to the CD44 knockout (Cd44−/− ) animals (white arrows point to MSU crystals in
DAPI-stained BMDMs; Figure 1D). This observation is consistent with the phagocytic role of the CD44
receptor and validates our earlier observations that PRG4, a CD44 ligand, prevents MSU phagocytosis
by macrophages [33]. Using flow cytometry to detect MSU phagocytosis via a change in macrophage
cell side-scatter [33], we observed that the CD44 receptor-ligand, HA, significantly reduced MSU
phagocytosis by THP-1 macrophages. Figure 1E depicts the representative flow cytometry plots of
MSU-treated macrophages in the absence or presence of HA (100 µg/mL). Two regions of interest were
identified: the P1 region (red), which represents the majority of macrophage cell population, and the
P2 region (purple) with increased side-scattering as a result of MSU phagocytosis. MSU treatment
appeared to increase the number of cells in the P2 region while HA co-treatment reduced the number of
cells in the P2 region. We previously validated this indirect phagocytosis assay against a direct method
of assessing crystal uptake by cells using cell counting under the microscope [33]. The quantitative
analysis of the percentage of macrophage cell population in the P2 region across different experimental
groups is shown in Figure 1F. HA significantly reduced MSU phagocytosis by THP-1 macrophages
(p < 0.01; Figure 1F). The efficacy of HA in reducing MSU phagocytosis by macrophages is likely to be
due to its ability to bind the CD44 receptor, resulting in receptor internalization [32]. This interaction
reduced the number of available CD44 surface receptors and thus attenuated macrophage phagocytic
activity against MSU crystals. Taken together, our findings establish the CD44 receptor as a promising
therapeutic target in gout, both through indirectly interfering with MSU phagocytosis by macrophages
and in facilitating the uptake of small molecules that have an intracellular target in macrophages.
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2.6.
Comparative
Binding of P6 Peptide and HA to CD44 Receptor and CD44 Dependent Association of P6

Peptide with THP-1 Macrophages

2.6. Comparative Binding of P6 Peptide and HA to CD44 Receptor and CD44 Dependent Association of P6
Peptide with
WeTHP-1
studiedMacrophages
the interaction between the P6 peptide and the CD44 receptor using a combination
of an ELISA binding assay and the association of fluorescein-labeled P6 peptide with THP-1
We studied the interaction between the P6 peptide and the CD44 receptor using a combination of
macrophages. We compared the binding affinity of the P6 peptide to the CD44 receptor using HA as
an ELISA
binding assay and the association of fluorescein-labeled P6 peptide with THP-1 macrophages.
a positive control. Using a concentration range between 1 ng/mL and 1 μg/mL, the P6 peptide and
We compared
the binding
affinity of the P6 peptide
to the
CD44
receptor
using
as and
a positive
control.
HA demonstrated
a concentration-dependent
binding
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CD44
receptor
(500 HA
ng/mL
1 μg/mL
Using
a
concentration
range
between
1
ng/mL
and
1
µg/mL,
the
P6
peptide
and
HA
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concentrations showed a higher binding compared to 1 ng/mL; p < 0.001; Figure 2A). Furthermore,
a concentration-dependent
to the
CD44the
receptor
(500 ng/mL
andbinding
1 µg/mL
showed
there was no significantbinding
difference
between
P6 peptide
and HA’s
to concentrations
CD44. Using flow
cytometry,
wecompared
observed that
peptideFigure
associates
THP-1 macrophages
h in
a higher
binding
to 1fluorescein-P6
ng/mL; p < 0.001;
2A).with
Furthermore,
there wasover
no 1significant

difference between the P6 peptide and HA’s binding to CD44. Using flow cytometry, we observed
that fluorescein-P6 peptide associates with THP-1 macrophages over 1 h in a concentration-dependent
manner (Figure 2B). In addition, pre-incubation of THP-1 macrophages with an anti-CD44 antibody
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2.7. Concentration-Dependent Internalization of Fluorescein-P6 Peptide in THP-1 Macrophages Using
2.7. Concentration-Dependent
Internalization of Fluorescein-P6 Peptide in THP-1 Macrophages Using
Confocal
Microscopy
Confocal Microscopy
The P6 peptide rapidly associated with the THP-1 macrophages in a concentration-dependent
The This
P6 peptide
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thecell-associated
THP-1 macrophages
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manner.
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mean
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to 1 mean
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µM concentrations
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<
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Figure 3A). We detected internalization of the P6 peptide in the THP-1 macrophages at the 10 and 25 µM
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Figure 3. Time and concentration-dependent
association of the fluorescein-P6 peptide with THP-1
macrophages and internalization of P6 peptide in macrophages following incubation for 6 h. THP-1
macrophages were counterstained for α-tubulin (red) and nuclei (blue). Data are presented as scatter
plots of three independent
0.001;
independent experiments
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with the
the mean
mean and
and standard
standard deviation
deviation highlighted.
highlighted. ** pp <
< 0.001;
***
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(B)Representative
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in THP-1
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at 66 h.
h. White
arrows point to co-localization of the fluorescein-P6 peptide with α-tubulin,
α-tubulin, indicating internalization
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macrophages. (C) The internalization of the P6 peptide in THP-1
THP-1 macrophages
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was
was higher
higher at
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25 µM
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compared to
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and10
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2.8. Cytotoxicity of P6 Peptide, Colchicine, and Colchicine-P6 Peptide Conjugate against Human THP-1
2.8. Cytotoxicity of P6 Peptide, Colchicine, and Colchicine-P6 Peptide Conjugate against Human THP-1
Macrophages
Macrophages
The impact of P6 peptide conjugation to colchicine on colchicine’s toxicity against THP-1
The impact of P6 peptide conjugation to colchicine on colchicine’s toxicity against THP-1
macrophages is shown in Figure 4. Colchicine demonstrated a dose-dependent cytotoxic effect
macrophages is shown in Figure 4. Colchicine demonstrated a dose-dependent cytotoxic effect
against macrophages over 24 h. At the lowest concentration (1 µM), macrophage cell viability was
against macrophages over 24 h. At the lowest concentration (1 μM), macrophage cell viability was
reduced by approximately 50%. At the highest concentration (25 µM), macrophage cell viability was
reduced by approximately 50%. At the highest concentration (25 μM), macrophage cell viability was
reduced by approximately 80%. In contrast, the P6 peptide demonstrated no cytotoxic effect against
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reduced by approximately 80%. In contrast, the P6 peptide demonstrated no cytotoxic effect against
THP-1 macrophages at the same concentration range as those of colchicine.
colchicine. At 25 µM,
μM, colchicine-P6
peptide
reduction
in macrophage
cell cell
viability
by approximately
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peptide treatment
treatmentresulted
resultedinina numerical
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in cell viability
of approximately
6% in 10 µM
This numerical
15%, compared
a reduction
in cell viability
of approximately
6% concentration.
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0.48 for
colchicine-P6
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(25 µM)).
InμM)).
addition,
the percentage
of viableofcells
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0.48 forvs.
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vs. colchicine-P6
(25
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colchicine-P6
peptide-treated
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was
significantly
higher
when
compared
to
corresponding
cells in colchicine-P6 peptide-treated macrophages was significantly higher when compared to
concentrations
colchicine-treated
macrophages (p macrophages
< 0.001 for all (p
comparisons),
and
not significantly
corresponding of
concentrations
of colchicine-treated
< 0.001 for all
comparisons),
and
different
from corresponding
P6 peptide
concentrations
(p > 0.05concentrations
for all comparisons).
The for
lack all
of
not significantly
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corresponding
P6 peptide
(p > 0.05
acomparisons).
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role
of
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The lack of a toxic effect from the colchicine-P6 peptide conjugate may be explained
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tothe
its
cell
membrane
and
is membrane
thus available
bind
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microtubules.
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in
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athe
CD44
receptor-mediated
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The internalization
of CD44
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other
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internalization
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peptide
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mechanism,
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and
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endosome that later fuses with the lysosome [32]. In this uptake mechanism, colchicine does not
the
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and
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cellular
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and is thus
unavailable
disrupt
the microtubules
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in
cell death)
interfere
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key cellular processes (e.g., ATP synthesis resulting in cell death) [32,36,37].

Figure 4. Impact of P6 peptide, colchicine, and colchicine-P6 peptide conjugate treatments on human
assay. P6 peptide and
THP-1 macrophage cell viability at 24 h using the Cell Counting Kit-8 (CCK-8) assay.
colchicine-P6 peptide treatments
treatments (1,
(1, 10, and 25 μM)
µM) showed no significant difference in cell viability
when
the the
control.
Colchicine
(1, 10, and
25 µM)
reduced macrophage
when compared
comparedwith
with
control.
Colchicine
(1, 10,
anddose-dependently
25 μM) dose-dependently
reduced
cell
viability. Data
are presented
plots as
of three
independent
experiments
withexperiments
at least duplicate
macrophage
cell viability.
Data as
arescatter
presented
scatter
plots of three
independent
with
wells
per
treatment.
Mean
standard
deviations
are highlighted.
p <highlighted.
0.001; n.s.: non-significant.
at least
duplicate
wells
per and
treatment.
Mean
and standard
deviations* are
* p < 0.001; n.s.:
non-significant.

2.9. Impact of P6 Peptide, Colchicine, and Colchicine-P6 Peptide Treatments on Monosodium Urate (MSU)
Crystal Phagocytosis by Human THP-1 Macrophages
2.9. Impact of P6 Peptide, Colchicine, and Colchicine-P6 Peptide Treatments on Monosodium Urate (MSU)
ThePhagocytosis
impact of P6bypeptide,
and colchicine-P6 peptide treatments on MSU phagocytosis by
Crystal
Human colchicine,
THP-1 Macrophages
THP-1 macrophages is shown in Figure 5. Following a 4 h incubation, THP-1 macrophages internalized
The impact of P6 peptide, colchicine, and colchicine-P6 peptide treatments on MSU phagocytosis
MSU crystals. P6 peptides (10 and 25 µM) significantly reduced MSU phagocytosis by THP-1 macrophages
by THP-1 macrophages is shown in Figure 5. Following a 4 h incubation, THP-1 macrophages
internalized MSU crystals. P6 peptides (10 and 25 μM) significantly reduced MSU phagocytosis by
THP-1 macrophages (Figure 5B, p < 0.001 for both comparisons). In addition, colchicine-P6 peptide
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(Figure 5B, p < 0.001 for both comparisons). In addition, colchicine-P6 peptide treatments (1, 10, and
25
µM) reduced
MSU
to a comparable
level as observed
with thelevel
P6 peptide
alone (pwith
< 0.001
treatments
(1, 10,
andphagocytosis
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MSU phagocytosis
to a comparable
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alone;
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againstMSU
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As
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1 macrophages.
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2.10. Anti-Inflammatory Efficacy of P6 Peptide, Colchicine, and Colchicine-P6 Peptide Treatments in
MSU-Stimulated THP-1 Macrophages
We initially studied the time-dependent ROS generation and IL-8 secretion following the incubation
of THP-1 macrophages with MSU crystals (100 µg/mL) (Figure 6A,B). At 6 h, MSU induced a significant
increase in intracellular ROS levels that corresponded to a significant increase in IL-8 secretion.
P6 peptide treatments (10 and 25 µM) reduced ROS generation and IL-8 secretion (1, 10, and 25 µM)
(Figure 6C,D; p < 0.001 for all comparisons against MSU alone). Colchicine-P6 peptide (1 µM and
10 µM) demonstrated superior efficacy in reducing ROS generation and IL-8 secretion compared to
corresponding P6 peptide concentrations (Figure 6C,D; p < 0.001 when comparing MSU + colchicine-P6
peptide vs. MSU + P6 peptide). The mean estimated reduction in ROS due to MSU + colchicine-P6
peptide treatment compared to the MSU + P6 peptide treatment was 27.0% at 10 µM concentration.
In addition, the mean estimated reduction in IL-8 secretion due to MSU + colchicine-P6 peptide
treatment compared to MSU + P6 peptide treatment was 43.8% at a 1 µM concentration and 24.2% at
a 10 µM concentration. The enhancement of the P6 peptide’s anti-inflammatory efficacy by colchicine
conjugation was biologically significant at 1 and 10 µM concentrations. Interestingly, this enhancing
effect disappeared at the 25 µM concentration due to the ceiling effect observed with the P6 peptide
effect. Colchicine alone reduced ROS generation (10 and 25 µM) and IL-8 secretion (1, 10, and 25 µM).
The superior efficacy of the colchicine-P6 peptide compared to P6 peptide alone is explained by the
colchicine moiety, which in itself possesses the ability to reduce ROS generation and downstream
IL-8 secretion.

concentration and 24.2% at a 10 μM concentration. The enhancement of the P6 peptide’s antiinflammatory efficacy by colchicine conjugation was biologically significant at 1 and 10 μM
concentrations. Interestingly, this enhancing effect disappeared at the 25 μM concentration due to the
ceiling effect observed with the P6 peptide effect. Colchicine alone reduced ROS generation (10 and
25 μM) and IL-8 secretion (1, 10, and 25 μM). The superior efficacy of the colchicine-P6 peptide
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Figure 6. Time-dependent impact of monosodium urate (MSU) crystals on the generation of reactive
Figure 6. Time-dependent impact of monosodium urate (MSU) crystals on the generation of reactive
oxygen
species
(ROS)
and
thethe
production
chemokine
interleukin-8
(IL-8)
by human
oxygen
species
(ROS)
and
productionof
of inflammatory
inflammatory chemokine
interleukin-8
(IL-8)
by human
THP-1
macrophages
and
anti-inflammatory
efficacy
of
the
P6
peptide,
colchicine,
and
colchicine-P6
THP-1 macrophages and anti-inflammatory efficacy of the P6 peptide, colchicine, and colchicine-P6
peptide in MSU stimulated THP-1 macrophages. Treatments with the P6 peptide, colchicine, and
colchicine-P6 peptide (1, 10, and 25 µM) were performed for 24 h followed by the addition of MSU
crystals (100 µg/mL) for 6 h followed by the determination of ROS generation by flow cytometry and
IL-8 production by enzyme-linked immunosorbent assay (ELISA). Data are presented as scatter plots
of three independent experiments with the mean and standard deviation highlighted. * p < 0.001; ** p
< 0.01; *** p < 0.05. (A) MSU increased ROS generation at 4 and 6 h treatments compared to 2 h. (B)
MSU increased IL-8 production by THP-1 macrophages at 6 h compared to 2 and 4 h. (C) Colchicine-P6
peptide was more efficacious than the P6 peptide alone at 1 and 10 µM in reducing ROS generation in
THP-1 macrophages. (D) Colchicine-P6 peptide was more efficacious than the P6 peptide alone at 1
and 10 µM in reducing IL-8 production by THP-1 macrophages.

2.11. Stability of P6 Peptide in Synovial Fluid (SF) Aspirates from Subjects with no History of Arthritis
We evaluated the time-dependent impact of normal SF (n = 3) incubation on P6 peptide stability
and determined the half-life of the P6 peptide under this condition. At 1 h of incubation, the mean
percentage of P6 peptide ± standard deviation (S.D.) recovered from SF was 47.6% ± 38.7% compared
to 45.1% ± 14.7% at 2 h, 40.2% ± 28.8% at 3 h, 49.2% ± 7.8% at 4 h, 36.5% ± 6.2% at 6 h, 18.4% ± 1.3%
at 12 h, and 6.4% ± 4.1% at 24 h (Figure S5, Supplementary Materials). The estimated half-life of the
P6 peptide in normal SF was approximately 4 h. In this regard, the P6 peptide has a longer half-life
compared to other peptides that bind surface antigens on immune cells, which showed a range of
half-life values between 10–100 min in SF [48]. The high variability in the recovery of the P6 peptide
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from the SF aspirates might be related to the low number of unique aspirates we studied, coupled with
reported high inter-donor variability [49]. The origin and composition of SF proteins are not entirely
understood. A limited number of studies have attempted to systematically characterize the proteome
of SF [50]. The SF proteome contains proteins secreted from cartilage, synovium, and proteins that
originate from plasma. In fact, SF protein composition shares many similarities with the protein
composition of plasma [50]. Therefore, the turnover of the P6 peptide is likely to be due to an intrinsic
tryptic protease activity derived from plasma [51].
3. Materials and Methods
3.1. Materials
N-Deacetylcolchicine was purchased from DSK Biopharma, Inc. (Morrisville, NC, USA). All amino
acids and resins were purchased from Advanced Automated Peptide Protein Technologies (APPTEC).
All other chemicals and reagents were purchased from Sigma-Aldrich. The chemical structures of final
products were confirmed by high-resolution MALDI-TOF (GT 0264) from Bruker Inc. and Bruker Impact
IITM UHR-QqTOF (Ultra-High Resolution Qq-Time-Of-Flight) mass spectrometry. Final compounds were
purified by a reversed-phase HPLC from Shimadzu (LC-20AP) using a gradient system of acetonitrile
and water and a reversed-phase preparative column (XBridge BEH130 Prep C18, Waters, Inc., Milford,
MA, USA). Phorbol 12-myristate-13-acetate (PMA), soluble uric acid, high-binding microtiter plates
(Corning), phosphate buffered saline (PBS), bovine serum albumin (BSA), fetal bovine serum (FBS),
and Tween 20 were purchased from Sigma Aldrich (St. Louis, MO, USA). The CD44-IgFc fusion
protein, HA, recombinant human IL-1β, IL-8 ELISA, and murine colony stimulating factor (M-CSF)
was purchased from R&D Systems (Minneapolis, MN, USA). Anti-human IgG Fc-HRP, DyLight 488
goat anti-mouse IgG, anti-CD44 antibody, anti-α-Tubulin antibody, fluoroshield-mounting medium
with DAPI, Cell Counting Kit-8 assay, and ROS assays were purchased from Abcam (Cambridge, MA,
USA). Human THP-1 monocytes and RPMI-1640 media were purchased from American Type Culture
Collection (ATCC) (Manassas, VA, USA). Pyrogen-free MSU crystals were obtained from Invivogen (San
Diego, CA, USA). Penicillin and Streptomycin cocktail and Turbo TMB-ELISA substrate were obtained
from ThermoFisher Scientific (Waltham, MA, USA). Normal SF aspirates were obtained from Articular
Engineering (Northbrook, IL, USA) from three donors with no history of arthritis within 24 h of death,
collected with partner site Institutional Review Board approval with informed consent from the nearest
relative. Cd44+/+ and Cd44−/− mice were obtained from Jackson Labs (Bar Harbor, ME, USA).
3.2. Methods
3.2.1. Synthesis of P6 Peptide
Fmoc Rink amide resin (0.57 mmol/g, 0.52 g) was swelled in DMF for 15–30 min under dry nitrogen.
The solvent (DMF) was filtered off after agitation. Piperidine in DMF (10 mL, 20% v/v) was used to remove
the Fmoc protecting group. Then, the first Fmoc protected amino acid (Fmoc-Phe-OH) (4 equiv.) was
coupled to the N-terminal of the resin using N,N,N0 ,N0 -tetramethyl-O-(1H-benzotriazol-1-yl)uranium
hexafluorophosphate, O-(benzotriazol-1-yl)-N,N,N0 ,N0 -tetramethyluronium hexafluorophosphate
(HBTU) (4 equiv.) and DIPEA (4 equiv.) in DMF under dry nitrogen for 1.5 h. Then, the reaction solution
was filtered out after completion of the coupling. The resin was washed off by DMF (10 mL, 3 × 2 min.).
Fmoc deprotection was done by adding piperidine in DMF (20% v/v, 10 mL, 3 × 10 min). The reaction
solution was filtered out and washed again with DMF. The subsequent Fmoc-protected amino acids were
coupled to the peptide template until the last amino acid (Fmoc-Trp(Boc)-OH) was coupled. The final
Fmoc deprotection was carried out to make a free N-terminal for the conjugation of colchicine. Cleavage
cocktail containing TFA, thioanisole, EDT and anisole (90:5:3:2 v/v/v/v, respectively, 6 mL) was used
to cleave the resin and all side chain-protecting groups form the peptide to check the final sequence.
The mixture was stirred at room temperature for 4 h. Then, the crude conjugate was precipitated using
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cold diethyl ether and centrifuged at 10 G for 10 min. The precipitant was dissolved in water containing
0.1% TFA and acetonitrile containing 0.1% TFA in an equal amount (1:1 v/v). After completion of the
synthesis of the 20 amino acid sequence of the P6 peptide, the linear peptide was confirmed by MALDI
analysis (m/z): C115 H165 N26 O30 calculated for M + H. 2390.2185, found 2389.9299 [M + H]+ .
3.2.2. Synthesis of Colchicine-Glutaryl Amide Conjugate
Coupling of N-deacetylcolchicine (35 mg, 0.098 mmol) with glutaric anhydride (11.97 mg,
0.105 mmol) was carried out by solution-phase chemistry in the presence of anhydrous tetrahydrofuran
(THF, 10 mL), 4-dimethylaminopyridine (DMAP, 8.5 mg, 0.07 mmol), and triethylamine (TEA, 31.5 µL,
0.23 mmol) as a base. The reaction mixture was stirred under nitrogen for 4 h. The solvent (THF)
was removed by a rotatory evaporator under reduced pressure and was then dissolved using DCM.
Hexane was used to crystallize the product (30 mg, 64%). The compound was used in conjugation
with resin-attached P6 peptide to afford the desired conjugate with the P6 peptide. Q-TOF analysis
(m/z): C25 H30 NO8 Calculated, 472.1971 for M + H; Found 472.2045 [M + H]+ , 494.1869 [M + Na]+ ,
510.1610 [M + K]+ ).
3.2.3. Synthesis of Colchicine-P6 Peptide Conjugate
The peptide-attached resin (230 mg) was used in the coupling with the colchicine-glutaryl amide
conjugate (30 mg, 0.075 mmol) synthesized by solution-phase chemistry. Anhydrous DMF (10 mL),
PyBOP (benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (58.5 mg, 0.11 mmol)),
1-hydroxybenzotriazole hydrate (HOBt, 30.3 mg, 0.22 mmol), and N, N-diisopropylethylamine
(DIPEA, 80 µL, 0.075 mmol) were added to the reaction mixture of the peptide-attached resin and
colchicine-glutaryl amide conjugate in 1 mL anhydrous DMF. This reaction mixture was shaken
on a rotator overnight. After the formation of the conjugate was confirmed by MALDI analysis,
the crude conjugate was washed for 2 h using DMF and DCM. The cleavage cocktail containing TFA,
thioanisole, EDT and anisole (90:5:3:2 v/v/v/v, respectively, 6 mL) was used to cleave the resin and
all side chain-protecting groups form the conjugate. The mixture was stirred at room temperature
for 4 h. Then, the crude conjugate was precipitated using cold diethyl ether and centrifuged at 10 G
for 10 min. The precipitant was dissolved in water containing 0.1% TFA and acetonitrile containing
0.1% TFA in an equal amount (1:1 v/v). After purification via reversed-phase HPLC and lyophilization
(3 mg), the structure of the conjugate was confirmed by high-resolution MALDI-TOF analysis (m/z):
C140 H192 N27 O37 Calculated, 2843.3972 for M + H, found 2843.8766 [M + H]+ .
3.2.4. Synthesis of Fluorescein-Labeled P6 Peptide
Protected P6 peptide-attached resin (170 mg) was used in the coupling with 5(6)-carboxyfluorescein
diisobutyrate on a solid support. Anhydrous DMF (10 mL), PyBOP (39 mg, 0.075 mmol), HOBt (20 mg,
0.15 mmol), and DIPEA (40 µL, 0.23 mmol) in 1 mL anhydrous DMF was added to the reaction
mixture of crude protected peptide-attached resin and 5(6)-carboxyfluorescein diisobutyrate (38.5 mg,
0.072 mmol). This reaction was shaken on a rotator overnight. After the formation of the compound
was confirmed by MALDI analysis, the resin was washed for 2 h using DMF and DCM. The cleavage
cocktail containing TFA, thioanisole, EDT, and anisole (90:5:3:2 v/v/v/v, respectively, 5 mL) was used to
cleave the resin and all side-chain protecting groups from the compound. The mixture was stirred at
room temperature for 4 h. Then, the crude was precipitated using cold diethyl ether and centrifuged at
10 G for 10 min. The precipitant was dissolved in water containing 0.1% TFA and acetonitrile containing
0.1 TFA in an equal amount (1:1 v/v) and was purified by reversed-phase HPLC. MALDI-TOF analysis
(m/z): C137 H179 N26 O35 Calculated. 2750.0860 for M + H, found 2749.6489 [M + H]+ .
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3.2.5. Differentiation of THP-1 Macrophages and CD44 Expression under Conditions of Inflammation,
Isolation of BMDMs from Cd44+/+ and Cd44−/− Animals and Impact of HA Treatment on MSU
Phagocytosis by THP-1 Macrophages
THP-1 monocytes were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated
FBS, 10 mM HEPES, 2 mM glutamine, 100 U/I penicillin, and 100 µg/mL streptomycin and maintained
at 37 ◦ C and 5% CO2 . THP-1 monocytes were differentiated into THP-1 macrophages using 50 ng/mL
phorbol-12-myristate 13-acetate (PMA) for 24 h [34]. Subsequently, adherent cells were washed twice
with serum-free medium and rested for another 24 h in PMA-free RPMI + 10% FBS medium. CD44
expression on THP-1 macrophages was conducted using flow cytometry following incubation with the
CD44-specific antibody (1:1000 dilution) for 1 h followed by cell pelleting and washing the cell pellet
with PBS. THP-1 macrophages were then incubated with DyLight 488 goat anti-mouse IgG at 1:1000
dilution for 30 min. Following cell pelleting and washing, cells were fixed in 4% paraformaldehyde and
cell-associated fluorescence was determined by flow cytometry using BD FACSVerse (BD Biosciences).
THP-1 macrophages (500,000 cells per well) were treated with IL-1β (10 ng/mL) or uric acid (10 mg/dL)
in serum-free RPMI 1640 medium for 24 h. THP-1 macrophages were washed with PBS, collected, and
CD44 expression was determined using flow cytometry as described above.
Cd44+/+ and Cd44−/− male mice (12–14 weeks old, n = 2 in each group) were euthanized, and
isolation and culture of bone marrow derived macrophages (BMDMs) were performed as previously
described using 10 ng/mL M-CSF [52]. BMDMs were seeded onto cover slips in 6-well plates (500,000
cells per well) and incubated with MSU crystals (100 µg/mL) for 4 h, followed by cell staining using
fluoroshield-mounting medium with DAPI and visualized under a microscope. All animal experiments
were approved by the Institutional Animal Care and Use Committee (IACUC) at Chapman University.
THP-1 macrophages (500,000 cells per well) were treated with MSU crystals (100 µg/mL) ± HA
(100 µg/mL) for 4 h. Subsequently, macrophages were collected, pelleted, and washed with PBS. MSU
phagocytosis was determined by analyzing the change in cell side-scatter using a flow cytometer.
Two regions of interest were identified: the P1 region representing the THP-1 macrophage population
in the absence of MSU crystal exposure and the P2 region with increased cell side scatter indicative
of MSU phagocytosis. Data are presented as the percentage of cells in the P2 region across different
experimental groups.
3.2.6. Comparative Binding of P6 Peptide and HA Using an Enzyme-Linked Immunosorbent Assay
(ELISA) Format
Wells of high-binding microtiter plates were coated with either the P6 peptide or high molecular
weight HA (molecular weight >1 million Da) in serial concentrations between 1 ng/mL and 1 µg/mL
overnight in phosphate buffered saline (PBS) (100 µL per well) at 4 ◦ C. To remove unbound molecules,
wells were washed with PBS + 0.05% Tween 20 and subsequently blocked using 2% bovine serum
albumin (BSA) (300 µL per well) for 2 h at room temperature. CD44-IgG Fc fusion protein (R&D Systems)
(0.1 µg/mL) in PBS + 0.05% Tween 20 (100 µL per well) was added to both coated and uncoated wells and
incubated for 1 h at room temperature. Following washing with PBS + 0.1% Tween 20, anti-human IgG
Fc-HRP (1:1000) was added and incubated at room temperature for 1 h, followed by washing three times
with PBS + 0.05% Tween 20. Turbo TMB-ELISA substrate solution was added (100 µL per well), and
absorbance intensity was determined at 450 nm. Absorbance values in the P6 peptide and HA-coated
wells were subtracted from the absorbance values of uncoated wells to adjust for any non-specific binding
by CD44-IgFc.
3.2.7. CD44-Dependent Association and Internalization of Fluorescein-P6 Peptide in THP-1
Macrophages
THP-1 macrophages (500,000 cells per well) were treated with different concentrations of the
fluorescein-labeled P6 peptide (1, 10, or 25 µM) for 30 or 60 min, after which cells were washed with
PBS, trypsinized, and fixed using 4% paraformaldehyde. Cell-associated fluorescence was determined
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by flow cytometry using BD FACSVerse. In a separate set of experiments, THP-1 macrophages were
pretreated with anti-CD44 antibody (2.5 µg/ml) for 1 h prior to the addition of fluorescence-labeled P6
peptide (1, 10 or 25 µM) for 1 h. Cell-associated fluorescence was determined as described above.
THP-1 macrophages (250,000 cells per well) were seeded in 4-well chamber slides followed by
treatment with different concentrations of the fluorescein-labeled P6 peptide (1, 10, or 25 µM) for
6 h. Subsequently, cells were fixed using 4% paraformaldehyde for 10 min followed by washing with
PBS and permeabilization with 0.1% Triton X-100 for 5 min. Following washing with PBS, cells were
blocked for 30 min in 2% BSA in PBS. Cells were then incubated with anti-α tubulin monoclonal
antibody (1:1000) for 2 h. Nuclear staining was performed using 4,6-diamidino-2-phenylindole (DAPI).
Confocal imaging and Z-stacking were performed using a Nikon Ti-E microscope. Intracellular mean
fluorescence was determined using three different fields in each group.
3.2.8. Cytotoxicity of P6 Peptide, Colchicine, and Colchicine-P6 Peptide against THP-1 Macrophages
THP-1 macrophages were plated in a 96-well plate at a density of 1 × 104 per well and treated with
different concentrations of P6 peptide, colchicine, colchicine-P6 peptide conjugate (1, 10, or 25 µM) for
24 h. Subsequently, 10 µL of CCK-8 solution was added to each well and absorbance was measured
90 min later at 450 nm. Cytotoxicity was expressed as the percentage of viable cells following treatments.
3.2.9. Impact of P6 Peptide, Colchicine, and Colchicine-P6 Peptide Treatments on MSU Phagocytosis
by THP-1 Macrophages and Downstream ROS Generation and IL-8 Secretion
THP-1 macrophages (500,000 cells per well) were incubated with the P6 peptide, colchicine,
or colchicine-P6 peptide at 1, 10, or 25 µM concentrations for 24 h. Subsequently, cells were treated
with MSU crystals (100 µg/mL) for 4 h. MSU phagocytosis by THP-1 macrophages was determined
using flow cytometry as described above.
THP-1 macrophages (500,000 cells per well) were treated with MSU crystals (100 µg/mL) for
2, 4, and 6 h. ROS staining solution (1:1000 ratio) was added to the wells and incubated for 1 h.
Subsequently, cells were collected, washed, and cell-associated fluorescence was determined using
flow cytometry. Media were collected at 2, 4, and 6 h, and IL-8 media concentrations were determined
by ELISA. In another set of experiments, THP-1 macrophages were incubated with the P6 peptide,
colchicine, or colchicine-P6 peptide at 1, 10, or 25 µM concentrations for 24 h. Subsequently, cells
were treated with MSU crystals (100 µg/mL) for 6 h. ROS generation and IL-8 concentrations were
determined as described above.
3.2.10. Stability of P6 Peptide in Normal Synovial Fluid (SF) Aspirates
P6 peptide stability in the presence of normal SF from three donors with no history of arthritis was
examined using an analytical reversed-phase high-performance liquid chromatography (RP-HPLC).
Using seven microcentrifuge tubes, a total of 50 µL of normal SF was diluted with 150 µL of PBS in
each tube. Following equilibrating diluted SF to 37 ± 1 ◦ C for 15 min, 50 µL of peptide stock solution
(1 mM solution in 100% sterile water) was added to each tube. Next, at different time intervals (0, 1, 2,
3, 4, 6, and 24 h), an aliquot of the reaction solution (100 µL) was sampled. Cold methanol (200 µL) was
added to each aliquot in order to precipitate proteins that were present in the SF. This was followed by
cooling the solution to 4 ◦ C for 15 min followed by centrifugation at 500 g for 15 min to precipitate SF
proteins. To determine the proteolytic stability of the P6 peptide, the supernatant was injected into
an analytical RP-HPLC C18 column. In order to measure the concentration of the P6 peptide isolated
from SF, the area under the curve (AUC) of the P6 peptide at each time point was estimated using
an average of four runs, and normalized to AUC values at time 0 and expressed as the percentage of
AUC at time 0.
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3.2.11. Statistical Analyses
Data were derived from at least three independent experiments with a minimum of duplicate
runs per group per experiment. Statistical significance comparing two groups or multiple groups
was assessed by the Student’s t-test or analysis of variance (ANOVA) followed by post-hoc pairwise
comparisons using Tukey’s post-hoc test. A p value of <0.05 was considered statistically significant.
4. Conclusions
In this study, we provided evidence supporting that CD44 expression is enhanced under conditions
characteristic of gout and that the CD44 receptor is directly involved in initiating inflammation by MSU
crystals in macrophages via facilitating the phagocytosis of MSU crystals. A 20 amino acid peptide ligand
of CD44, the P6 peptide, showed a similar binding profile to CD44 as that of HA and the association and
internalization of the P6 peptide by human THP-1 macrophages was CD44-dependent. We successfully
synthesized a colchicine-P6 peptide conjugate with a hydrolyzable glutaryl amide linker. The conjugation
of colchicine to the P6 peptide abolished the cytotoxic effect of colchicine against THP-1 macrophages at
a concentration range between 1 and 25 µM. The colchicine-P6 peptide reduced MSU phagocytosis by
THP-1 macrophages due to the ability of the P6 peptide moiety to bind CD44, thus attenuating CD440 s
role in mediating MSU phagocytosis. On the other hand, the colchicine-P6 peptide conjugate showed
superior efficacy in reducing ROS generation and IL-8 secretion, potentially due to the contribution of
the colchicine moiety where colchicine was efficacious in reducing ROS generation and downstream
inflammatory chemokine production. The stability of the P6 peptide in normal SF was better than
previously reported peptides that bind immune cells in SF. Taken together, conjugation of colchicine to
the P6 peptide minimized the off-target cytotoxic effect of colchicine and preserved the anti-inflammatory
effect of colchicine with the P6 peptide moiety playing an effector role in reducing MSU phagocytosis and
downstream inflammation in macrophages. The colchicine-P6 peptide is a potential novel therapeutic in
gout and future work will evaluate the kinetics and efficacy of the intra-articular colchicine-P6 peptide in
an animal model of acute gouty arthritis. To our knowledge, this is the first report demonstrating the
utility of a colchicine-peptide conjugate as an anti-inflammatory therapeutic.
Supplementary Materials: The MALDI spectra of selected compounds and P6 peptide stability in normal SF
aspirates are provided.
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